Literature DB >> 10577657

Glaucoma.

A L Coleman1.   

Abstract

In 2000 an estimated 66.8 million people worldwide will have glaucoma, 6.7 million of whom will be bilaterally blind from irreversible optic-nerve damage. Yet even in developed countries with public educational programmes that target glaucoma, half of the individuals with glaucoma remain undiagnosed. Patients with even mild visual impairment secondary to glaucoma may have difficulties with mobility, driving, and social interactions. Although glaucoma may be associated with increased eye pressures, its diagnosis does not rely on a specific level of eye pressure. Diagnosis of glaucoma often relies on examination of the optic disc and assessment of the visual field. The two most common types of glaucoma--primary open-angle glaucoma and primary angle-closure glaucoma--have different risk factors. Although similar medications can be used to treat these two types of glaucoma, the overall management of patients differs in important ways. Until recently, there were no randomised clinical trials that showed the effectiveness of lowering eye pressures with medications or surgery in patients with glaucoma. However, in 1998 a randomised clinical trial showed the benefit of lowering eye pressure in patients with glaucoma who had eye pressures of 24 mm Hg or less. Because glaucoma is treatable, and because the visual impairment from glaucoma is irreversible, early detection of the disease is critically important.

Entities:  

Mesh:

Year:  1999        PMID: 10577657     DOI: 10.1016/S0140-6736(99)04240-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  71 in total

1.  [Do we take care of glaucoma from primary care?].

Authors:  N Marañón Heinrich; J Jaén Díaz; I Sanz Alcolea; F López De Castro
Journal:  Aten Primaria       Date:  2001-03-31       Impact factor: 1.137

2.  Central corneal thickness as a predictor of visual field loss in primary open angle glaucoma for a Hispanic population.

Authors:  Jorge L Fernandez-Bahamonde; Christian Roman-Rodriguez; Maria C Fernandez-Ruiz
Journal:  Semin Ophthalmol       Date:  2011-01       Impact factor: 1.975

3.  Optic nerve oxygen tension: the effects of timolol and dorzolamide.

Authors:  J F Kiilgaard; D B Pedersen; T Eysteinsson; M la Cour; K Bang; P K Jensen; E Stefánsson
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

4.  Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population.

Authors:  J T F Lau; V Lee; D Fan; M Lau; J Michon
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

5.  Genetic research and health disparities.

Authors:  Pamela Sankar; Mildred K Cho; Celeste M Condit; Linda M Hunt; Barbara Koenig; Patricia Marshall; Sandra Soo-Jin Lee; Paul Spicer
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

Review 6.  Spectral domain optical coherence tomography and glaucoma.

Authors:  Teresa C Chen; Audrey Zeng; Wei Sun; Mircea Mujat; Johannes F de Boer
Journal:  Int Ophthalmol Clin       Date:  2008

7.  Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma.

Authors:  Seong Hee Shim; Joon Mo Kim; Chul Young Choi; Chan Yun Kim; Ki Ho Park
Journal:  J Med Food       Date:  2012-08-07       Impact factor: 2.786

8.  The bugeye mutant zebrafish exhibits visual deficits that arise with the onset of an enlarged eye phenotype.

Authors:  Joseph M Stujenske; John E Dowling; Farida Emran
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-13       Impact factor: 4.799

9.  Extracellular release of ATP mediated by cyclic mechanical stress leads to mobilization of AA in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Jianming Qiu; Pratap Challa; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

10.  Investigation of the association between CALCRL polymorphisms and primary angle closure glaucoma.

Authors:  Dan Cao; Xing Liu; Xiangming Guo; Yanhong Cong; Jingjing Huang; Zhen Mao
Journal:  Mol Vis       Date:  2009-10-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.